These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30271152)

  • 41. Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland.
    Reymann S; Schoretsanitis G; Egger ST; Mohonko A; Kirschner M; Vetter S; Homan P; Seifritz E; Burrer A
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting.
    Hodgson RE
    Clinicoecon Outcomes Res; 2019; 11():517-524. PubMed ID: 31616168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
    Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
    CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics.
    Lin CH; Chan HY; Wang FC; Hsu CC
    Ther Adv Psychopharmacol; 2022; 12():20451253221079165. PubMed ID: 35340566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches.
    Højlund M; Correll CU
    Expert Opin Pharmacother; 2023; 24(13):1463-1489. PubMed ID: 37345508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
    Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH
    Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.
    Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
    Clin Drug Investig; 2021 Jan; 41(1):99-113. PubMed ID: 33331979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.
    Blackwood C; Sanga P; Nuamah I; Keenan A; Singh A; Mathews M; Gopal S
    Patient Prefer Adherence; 2020; 14():1093-1102. PubMed ID: 32753849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Oya K; Iwata N
    Psychiatry Res; 2016 Dec; 246():750-755. PubMed ID: 27863801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
    Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risperidone (depot) for schizophrenia.
    Sampson S; Hosalli P; Furtado VA; Davis JM
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD004161. PubMed ID: 27078222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study.
    Miron AA; Petric PS; Teodorescu A; Ifteni P; Chele G; Szalontay AS
    Brain Sci; 2023 Jan; 13(2):. PubMed ID: 36831716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan.
    Misawa F; Okumura Y; Takeuchi Y; Fujii Y; Takeuchi H
    Schizophr Res; 2021 May; 231():42-46. PubMed ID: 33752105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Acting Injectable Antipsychotics in Children and Adolescents.
    Lytle S; McVoy M; Sajatovic M
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):2-9. PubMed ID: 28112539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update.
    Gentile S
    Horm Mol Biol Clin Investig; 2017 Jun; 36(2):. PubMed ID: 28672735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Off-label use of second-generation antipsychotics in borderline personality disorder: a comparative real-world study among oral and long-acting injectables in Spain.
    García-Carmona JA; Simal-Aguado J; Campos-Navarro MP; Valdivia-Muñoz F; Galindo-Tovar A
    Int Clin Psychopharmacol; 2021 Jul; 36(4):201-207. PubMed ID: 33853106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-acting Injectable vs. Oral Antipsychotics: Adherence, Persistence and Switching over three Years of Real-life Analysis.
    Romagnoli A; Santoleri F; Costantini A
    Curr Rev Clin Exp Pharmacol; 2021; 16(1):109-116. PubMed ID: 32148198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.